angiotensin IV comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
=== Europe === Marketing authorisation for 177Lu-DOTATATE was granted by the European Medicines Agency on 26 September 2017. 90Y-DOTATOC (international nonproprietary name: yttrium (90Y) edotreotide) and 177Lu-DOTATOC are designated as orphan drugs, but have not yet received marketing authorisation.
Dermatitis repens (acrodermatitis continua, acrodermatitis continua of Hallopeau, acrodermatitis continua suppurativa Hallopeau, acrodermatitis perstans, dermatitis repens Crocker, Hallopeau's acrodermatitis, Hallopeau's acrodermatitis continua, pustular acrodermatitis) Infantile acropustulosis (acropustulosis of infancy) Palmoplantar pustulosis (persistent palmoplantar pustulosis, pustular psoriasis of the Barber type, pustular psoriasis of the extremities, pustulosis of palms and soles, pustulosis palmaris et plantaris) Pustular bacterid
Allows performance beyond the usual pain threshold. Some painkillers raise blood pressure, increasing oxygen supply to muscle cells. Painkillers used by athletes range from common over-the-counter medicines which include NSAIDs (ibuprofen) to powerful prescription narcotics.
Sources: en.wikipedia.org
== External links == Controlled vocabulary of post-translational modifications in Uniprot List of posttranslational modifications in ExPASy Browse SCOP domains by PTM — from the dcGO database Overview and description of commonly used post-translational modification detection techniques
The research was continued by Lehmann who started a systematic study, first of cholesteryl benzoate, and then of related compounds which exhibited the double-melting phenomenon. He was able to make observations in polarized light, and his microscope was equipped with a hot stage (sample holder equipped with a heater) enabling high temperature observations. The intermediate cloudy phase clearly sustained flow, but other features, particularly the signature under a microscope, convinced Lehmann that he was dealing with a solid. By the end of August 1889 he had published his results. Lehmann's paper prompted work by Ludwig Gattermann who in 1890 published a paper on the synthesis of azoxyphenol ethers, such as para-azoxyanisole, which exhibited the same double-melting behaviour. Lehmann's interpretation of his results was controversial, and was not accepted by Gustav Heinrich Tammann, Georg Hermann Quincke, and Walther Nernst. In 1905 research by Rudolf Schenck addressed and largely resolved the objections of Tamman, Quincke and Nernst. Lehmann's work was continued and significantly expanded by the German chemist Daniel Vorländer who from the beginning of the 20th century had synthesized most of the liquid crystals known. In 1910–1922 research on liquid crystals, led by Georges Friedel, was carried on in France. In the period before X-rays liquid crystals were seen as merely a curiosity by scientists, and the field did not yield applications until the second half of the 20th century.
Now differences between the contemporary squid and octopus samples became very clear. In the octopus, broad bands of fibers passed across the plane of the tissue and were separated by equally broad bands arranged in a perpendicular direction. In the squid there were narrower but also relatively broad bundles arranged in the plane of the section, separated by thin partitions of perpendicular fibers. It seemed I had found a means to identify the mystery sample after all. I could distinguish between octopus and squid, and between them and mammals, which display a lacy network of connective tissue fibers. After 75 years, the moment of truth was at hand. Viewing section after section of the St. Augustine samples, we decided at once, and beyond any doubt, that the sample was not whale blubber. Further, the connective tissue pattern was that of broad bands in the plane of the section with equally broad bands arranged perpendicularly, a structure similar to, if not identical with, that in my octopus sample. The evidence appears unmistakable that the St. Augustine sea monster was in fact an octopus, but the implications are fantastic. Even though the sea presents us from time to time with strange and astonishing phenomena, the idea of a gigantic octopus, with arms 75 to 100 feet in length and about 18 inches in diameter at the base—a total spread of some 200 feet—is difficult to comprehend.
Troops decapitated their bodies and displayed their heads along a public road to strike fear into those tempted to accept the Democratic Republic of Vietnam's sovereignty. Massacres did not start with the Americans in My Lai, or the Vietnamese communists in Hue in 1968. And yet, the French Union's massacre of over two hundred Vietnamese women and children in My Tratch in 1948 remains virtually unknown in France to this day. The French Army also utilized torture against Việt Minh prisoners. Benjamin Valentino estimates that the French were responsible for 60,000 to 250,000 civilian deaths.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.